

RESEARCH PAPER

Cannabidiol inhibits angiogenesis by multiple mechanisms

M Solinas^{1*}, P Massi^{2*}, AR Cantelmo^{3*}, MG Cattaneo^{2*}, R Cammarota^{3*}, D Bartolini³, V Cinquina¹, M Valenti¹, LM Vicentini², DM Noonan⁴, A Albini^{3**} and D Parolaro^{1**}

¹Department of Biomedical, Computer and Communication Sciences, University of Insubria, Busto Arsizio (VA), Italy, ²Department of Pharmacology, Chemotherapy and Toxicology, University of Milan, Milan, Italy, ³Oncology Research Laboratory, Science and Technology Park, IRCCS MultiMedica, Milan, Italy, and ⁴Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy

Correspondence

Daniela Parolaro, Department of Biomedical, Computer and Communication Sciences, Centre of Neuroscience, University of Insubria, Busto Arsizio (VA) 21052, Italy. E-mail: daniela.parolaro@uninsubria.it

*These authors equally contributed to the work.

**These authors share the seniorship.

Keywords

cannabidiol; angiogenesis; HUVEC; migration; invasion; tube formation

Received

6 December 2011

Revised

16 May 2012

Accepted

21 May 2012

BACKGROUND AND PURPOSE

Several studies have demonstrated anti-proliferative and pro-apoptotic actions of cannabinoids on various tumours, together with their anti-angiogenic properties. The non-psychoactive cannabinoid cannabidiol (CBD) effectively inhibits the growth of different types of tumours *in vitro* and *in vivo* and down-regulates some pro-angiogenic signals produced by glioma cells. As its anti-angiogenic properties have not been thoroughly investigated to date, and given its very favourable pharmacological and toxicological profile, here, we evaluated the ability of CBD to modulate tumour angiogenesis.

EXPERIMENTAL APPROACH

Firstly, we evaluated the effect of CBD on human umbilical vein endothelial cell (HUVEC) proliferation and viability – through [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay and FACS analysis – and *in vitro* motility – both in a classical Boyden chamber test and in a wound-healing assay. We next investigated CBD effects on different angiogenesis-related proteins released by HUVECs, using an angiogenesis array kit and an ELISA directed at MMP2. Then we evaluated its effects on *in vitro* angiogenesis in treated HUVECs invading a Matrigel layer and in HUVEC spheroids embedded into collagen gels, and further characterized its effects *in vivo* using a Matrigel sponge model of angiogenesis in C57/BL6 mice.

KEY RESULTS

CBD induced HUVEC cytostasis without inducing apoptosis, inhibited HUVEC migration, invasion and sprouting *in vitro*, and angiogenesis *in vivo* in Matrigel sponges. These effects were associated with the down-modulation of several angiogenesis-related molecules.

CONCLUSIONS AND IMPLICATIONS

This study reveals that CBD inhibits angiogenesis by multiple mechanisms. Its dual effect on both tumour and endothelial cells supports the hypothesis that CBD has potential as an effective agent in cancer therapy.

Abbreviations

ET-1, endothelin-1; HUVECs, human umbilical vein endothelial cells; PDGF-AA, platelet-derived growth factor-AA; TIMP1, tissue inhibitor of metalloproteinases 1; uPA, urokinase-type plasminogen activator

Introduction

Several studies have demonstrated that cannabinoids exert an inhibitory action on the proliferation of various cancer cell lines, and are able to slow down or arrest the growth of different models of tumour xenograft in experimental animals (for review see Flygare and Sander, 2008; Alexander *et al.*, 2009; Freimuth *et al.*, 2010; Guindon and Hohmann, 2011). These data have attracted increasing interest for clinical exploitation of cannabinoid-based anti-cancer therapies.

Recently, in addition to their anti-proliferative and pro-apoptotic actions, it has been shown that cannabinoids can affect other important processes in tumorigenesis, in particular angiogenesis. Angiogenesis, the formation of new blood vessels from the pre-existing ones, represents an essential part of tumour growth, invasion and metastasis and constitutes a therapeutic target for cancer therapy. Diverse complex cellular actions are implicated in angiogenesis, such as extracellular matrix degradation, migration and proliferation of endothelial cells, morphological differentiation of endothelial cells to form tubes. All of these processes require a finely tuned balance between stimulating and inhibitory signals. Stimulating signals include growth factors, such as VEGF, integrins, angiopoietins, chemokines, as well as other factors (Folkman, 2007; Chung *et al.*, 2010). Molecules inducing inhibitory signals include thrombospondin, interferons and other cytokines as well as other endogenous angiogenesis inhibitory factors, which may target endothelial cells either directly or indirectly (Noonan *et al.*, 2008; 2011a; Albin *et al.*, 2009; 2010).

Cannabinoids that bind to the CB₁ and/or CB₂ cannabinoid receptors (WIN5512-2, HU210, JWH133 and THC) have been reported to inhibit vascular endothelial cell survival and migration (Blázquez *et al.*, 2003) as part of their anti-angiogenic action. Treatment with these cannabinoids reduces vascular density in experimental tumours (Blázquez *et al.*, 2003; 2006; Casanova *et al.*, 2003; Portella *et al.*, 2003; Preet *et al.*, 2008). Met-fluoro-anandamide, a metabolically stable analogue of the endocannabinoid anandamide, has been demonstrated to inhibit spreading of endothelial cell spheroids, reduce capillary-like tube formation *in vitro* and suppress angiogenesis in an *in vivo* chick chorioallantoic membrane assay (Pisanti *et al.*, 2007). In addition, cannabinoids are also able to suppress pro-angiogenic factor production (Casanova *et al.*, 2003; Blázquez *et al.*, 2004; Preet *et al.*, 2008) as well as directly induce apoptosis of the endothelial cells.

Although cannabinoids have a favourable drug safety profile, their clinical use in cancer therapy is impaired by their psychoactivity and psychotropic side effects, mediated largely by their interaction with the neuronal CB₁ cannabinoid receptor, or by their immune depressant effects, mediated by the peripheral CB₂ cannabinoid receptor subtype. More strategic approaches are aimed at the use of natural non-psychoactive cannabinoids that bind with very low affinity to cannabinoid receptors, thus excluding either psychotropic and/or immune/peripheral effects (Gertsch *et al.*, 2010; Russo, 2011).

The non-psychoactive cannabinoid, cannabidiol (CBD), which has a very low affinity for both CB₁ and CB₂ cannabinoid receptors, but variably interferes with transient receptor

potential (TRP) receptors (De Petrocellis *et al.*, 2011) and PPAR receptors (O'Sullivan and Kendall, 2010), has been reported to inhibit the growth of several tumours (Ligresti *et al.*, 2006; Ramer *et al.*, 2010a,b; McAllister *et al.*, 2011; Shrivastava *et al.*, 2011), including glioma (Massi *et al.*, 2004; 2006; 2008; Vaccani *et al.*, 2005; Marcu *et al.*, 2010; Torres *et al.*, 2011), both *in vitro* and *in vivo*. Treatment of glioma cells with CBD triggered apoptosis/autophagy, caspase cascade activation, oxidative stress as well as modulation of the lipoxygenase pathway and the endocannabinoid system (Massi *et al.*, 2004; 2006; 2008; Vaccani *et al.*, 2005; Marcu *et al.*, 2010; Torres *et al.*, 2011).

The anti-angiogenic properties of CBD have not been thoroughly investigated to date. Given its very favourable pharmacological and toxicological profile, here, we investigated the anti-angiogenic properties of CBD on human umbilical vein endothelial cells (HUVECs). We found that CBD induced endothelial cell cytostasis without inducing apoptosis, inhibited endothelial cell migration, invasion and sprouting *in vitro* and inhibited angiogenesis *in vivo*. These effects were associated with a down-modulation of several molecules associated with angiogenesis, including MMP2 and MMP9, urokinase-type plasminogen activator (uPA), endothelin-1 (ET-1), platelet-derived growth factor-AA (PDGF-AA) and chemokine (c-x-c motif) ligand 16 (CXCL16).

Taken together, our results provide a wide spectrum characterization of the anti-angiogenic effects of CBD on HUVECs and its dual effect on both cancer and endothelial cells supports the hypothesis that CBD could represent a potential effective agent in cancer therapy.

Methods

Reagents

Standard chemicals and cell culture reagents were purchased from Sigma-Aldrich Srl (Milan, Italy).

Murine recombinant VEGFA and murine recombinant TNF- α were purchased from Peprotech (Offenbach, Germany); heparin was obtained from Sigma (Sigma-Aldrich Chemie, Taufkirchen, Germany).

CBD was a generous gift from GW Pharmaceuticals (Salisbury, UK). It was initially dissolved in ethanol to a concentration of 50 mM and stored at -20°C and further diluted in complete tissue culture medium; final ethanol concentration never exceeded 0.05%.

Cell cultures

HUVECs were either isolated from umbilical cords by digestion with collagenase as described by Jaffe *et al.* (1973) or purchased from Promo Cell (Heidelberg, Germany) or Lonza (Basel, Switzerland). These former cells were routinely grown in 199 medium (M199), supplemented with 20% heat-inactivated fetal bovine serum (FBS), 25 $\mu\text{g}\cdot\text{mL}^{-1}$ endothelial cell growth factor and 50 $\mu\text{g}\cdot\text{mL}^{-1}$ heparin. The latter were grown in endothelial growth medium as indicated by the provider. All cells were maintained at 37°C in a humidified 5% CO₂ atmosphere and used between the second and eighth passage *in vitro*.

For *in vitro* studies, cells were seeded in complete medium, and after 24 h incubation, the medium was replaced by

medium with 2% FBS containing the compound to be tested at the indicated concentrations.

MTT test

To determine the effects of CBD on cell proliferation, the [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) colorimetric assay was carried out as previously reported (Massi *et al.*, 2004). Briefly, HUVECs were seeded in complete medium in a 96-well flat bottom multiwell at a density of 1×10^4 cells per well. After 24 h, the medium was replaced by medium with 2% FBS and $2 \text{ ng}\cdot\text{mL}^{-1}$ VEGF and cells were treated with CBD at the indicated concentrations for 24 h. At the end of the incubation with the drug, MTT ($0.5 \text{ mg}\cdot\text{mL}^{-1}$ final concentration) was added to each well and the incubation was continued for a further 4 h. The insoluble formazan crystals were solubilized by the addition of $100 \mu\text{L}$ of 100% dimethyl sulfoxide. Plates were read at 570 nm, using an automatic microtitre plate reader and % control was calculated as the absorbance of the treated cells per control cells $\times 100$.

Cytofluorimetric analysis

HUVECs (6×10^5) were incubated with different concentrations of CBD for 24 h in 2% FBS complete medium. Cells were then recovered, washed twice with PBS and transferred to test tubes. Cells were pelleted and resuspended in Annexin V-binding buffer (0.01 M HEPES (pH 7.4) and 0.14 M NaCl; 2.5 mM CaCl_2). Fluorescein isothiocyanate Annexin V and 7-amino-actinomycin D (BD Biosciences, San Jose, CA, USA) were added to each test tube and incubated for 15 min at room temperature in the dark. Cells were then washed in PBS, supernatants discarded and resuspended in $400 \mu\text{L}$ of binding buffer. Samples were acquired by flow fluorocytometry using a FACSCanto (BD Biosciences) and analysed using FACSDiva Software 6.1.2. The experiment was performed twice and each condition was in duplicate.

Cell migration assay – Boyden chamber and scratch wound-healing assay

HUVEC migration assays were performed in a 48-well modified Boyden chamber as previously described (Cattaneo *et al.*, 2008). Briefly, Nucleopore polyvinylpyrrolidone-free polycarbonate filters ($8 \mu\text{m}$) coated with $10 \mu\text{g}\cdot\text{mL}^{-1}$ of type IV collagen were placed over a bottom chamber containing M199 supplemented with 10% FBS as attractant factor. The cells, suspended in M199 containing 1% fatty acid free BSA, were incubated for 1 h with the indicated concentrations of CBD, and then added to the upper chamber at a density of 5×10^4 cells per well. CBD was continuously present during the experiments. After 6 h of incubation at 37°C , non-migrated cells on the upper surface of the filter were removed by scraping. The cells migrated to the lower side of the filter were stained with Diff-quick stain, and 5 unit fields per filter were counted at $160 \times$ magnification with a microscope (Zeiss, Oberkochen, Germany). The assays were run in triplicate.

To investigate HUVEC migration, the cells were seeded at a concentration of 4×10^4 cells/ $500 \mu\text{L}^{-1}$ medium per well in 24-well culture plates. After 24 h, confluent monolayers were 'scratched' with a plastic pipette tip to create a uniform, cell-free 'wound' area and treated with CBD at the indicated

concentrations. The gap created and the time required for cells to migrate into the area were recorded by phase contrast microscopy using a $10\times$ objective, at 0, 16 and 24 h. At each time point, eight photographs of each wound area were taken and the migratory effect was quantified by counting the cells present in the gap using ImageJ software.

Human array kit/proteome profiler

To analyse the expression profiles of tumour-related proteins, we used the Proteome Profiler™ Human Antibody Array Kit (R&D Systems, Ltd, Abingdon, UK), according to the manufacturer's instructions. This kit uses an array of 55 antibodies directed at proteins involved in angiogenesis and invasiveness, spotted onto a nitrocellulose membrane. Briefly, HUVECs were seeded in complete medium in a 24-well flat bottom multiwell at a density of 9.6×10^4 cells per well⁻¹. After 24 h, the medium was replaced by medium with 2% FBS and $2 \text{ ng}\cdot\text{mL}^{-1}$ VEGF and cells were treated with CBD at the indicated concentrations for 24 h. Supernatants of CBD-treated and untreated HUVECs (1 mL) were centrifuged and mixed with $15 \mu\text{L}$ of biotinylated detection antibodies for 1 h at room temperature. Then the membranes were incubated with the sample/antibody mixtures overnight at 4°C on a rocking platform. Following a washing step to remove unbound material, streptavidin–horseradish and chemiluminescent detection reagents were added sequentially. The intensity of chemiluminescence was captured on X-ray film and the data quantified by scanning on a transmission-mode scanner and analysing the array image file using ImageJ analysis software.

ELISA

The release of MMP2 from CBD-treated and -untreated HUVECs was evaluated by an ELISA according to the manufacturer's instructions (R&D Systems Ltd). Briefly, HUVECs were seeded in complete medium in a 24-well flat bottom multiwell at a density of 5×10^4 cells per well. After 24 h, the medium was replaced by medium with 2% FBS and $2 \text{ ng}\cdot\text{mL}^{-1}$ VEGF and cells were treated with CBD at the indicated concentrations for 24 h. At the end of the incubation period, supernatants were collected, centrifuged and protein content was determined according to BCA assay (Pierce, IL, USA). Samples ($50 \mu\text{L}$) were added to individual wells in a microwell plate commercially coated with a polyclonal antibody against human MMP2. After 2 h at room temperature, the wells were washed and detection antibody against MMP2 conjugated to horseradish peroxidase was added. The wells were then washed and substrate solution, containing both hydrogen peroxide and tetramethylbenzidine as chromogen, was added for 30 min at room temperature. After the addition of the stop solution, colour intensity was measured at 450 nm in a microplate reader (EL800, Bio-Tek, Winooski, VT, USA). The absorbance values of the unknown samples were within the linearity range of the ELISA test, assessed by calibration curves obtained with known amounts of MMP2.

Western blotting

HUVECs were plated in complete medium and after adhesion were treated with increasing concentrations of CBD in the presence of 2% FBS. After 24 h, cells were collected by brief trypsinization and total lysates were prepared using Cell Lysis

Buffer (Cell Signaling Technology, Beverly, MA, USA). Protein concentrations were evaluated by the DC Protein Assay (Bio-Rad, Hercules, CA, USA). Equal amounts of proteins for each sample were resolved on 10% SDS-PAGE and blotted onto nitrocellulose membranes (Amersham, Biosciences, Otelfingen, CH). Following blocking with 5% non-fat milk powder ($w v^{-1}$) in Tris-buffered saline (10 mM Tris-HCl, pH 7.5, 100 mM NaCl, 0.1% Tween-20) for 1 h at room temperature, membranes were incubated with primary antibodies directed against the human antigens MMP2 and uPA (5B4 clone), both kindly provided by Prof Mario Del Rosso (Department of Experimental Pathology and Oncology, University of Florence) and an anti- α -tubulin antibody used for normalizing protein loading. The antibodies were diluted in 5% BSA, Tris-buffered saline, 0.1% Tween-20 and 5% milk powder, Tris-buffered saline, 0.1% Tween-20, respectively. The bound antibodies were visualized by horseradish-peroxidase-conjugated secondary antibodies and an enhanced chemiluminescence detection system from Amersham Biosciences (Pittsburgh, PA, USA).

Zymographic analysis

Zymography was performed by electrophoresis of 10 μ g of proteins extracted from HUVECs treated with different concentrations of CBD as for Western blotting, but without heating the samples, in 10% polyacrylamide containing 0.1% gelatin in the presence of SDS. After electrophoresis, the gels were incubated for 30 min at room temperature with gentle agitation in Renaturing Buffer (Invitrogen, Eugene, OR, USA) and overnight at 37°C in the Developing Buffer (Invitrogen). The gels then were stained for 30 min with Coomassie® G-250 stain (Invitrogen), which visualizes areas where the gelatin has been removed by enzymatic activity. The resulting bands were acquired with an Epson Perfection V750 pro scanner (Syngene, Cambridge, UK).

Matrigel morphogenesis assay

The effects of CBD on the ability of HUVECs to reorganize and differentiate into capillary-like networks were also assessed in the *in vitro* Matrigel morphogenesis assay. A 24-multiwell plate, pre-chilled at -20°C, was carefully filled with 300 μ L per well of liquid Matrigel (10 mg·mL⁻¹) at 4°C with a pre-chilled pipette, avoiding bubbles. The Matrigel was then polymerized for 1 h at 37°C. HUVECs (5 × 10⁴ cells per well) were suspended in 1 mL of complete medium supplemented with 2% FBS in the absence or presence of different concentrations of CBD at the indicated concentrations, and carefully layered on the top of the polymerized Matrigel. Effects on the growth and morphogenesis of HUVECs were recorded after 6 h incubation with an inverted microscope (Leica DM-IRB, Leitz Microsystems, Wetzlar, Germany) equipped with charge-coupled device optics and a digital analysis system.

In vitro angiogenesis assay from spheroids

HUVEC spheroids were generated as described by Korff and Augustin (1998). In brief, a specific number of HUVECs (1 × 10³ cells per well) were suspended in M199-containing 10% FBS and 0.25% ($w v^{-1}$) carboxymethylcellulose, and seeded in non-adherent round bottom 96-well plates. Under these conditions, single suspended cells contribute to the formation of an endothelial cell-derived spheroid.

In order to quantify *in vitro* angiogenesis, HUVEC spheroids were embedded into collagen gels. Briefly, 50–100 HUVEC spheroids were suspended in 0.3 mL of 20% FBS containing 0.9% ($w v^{-1}$) carboxymethylcellulose, and mixed with 0.3 mL of a collagen stock solution prepared by mixing at 4°C acidic rat tail collagen (5 mg·mL⁻¹; 8 vol) with 10× M199 and 0.1 M NaOH to adjust the pH to 7.4. The various test substances were added to the suspended spheroids before embedding them into collagen. The spheroid-containing gel was rapidly transferred into pre-warmed 24-well plates, and incubated for 48 h at 37°C in 5% CO₂. In-gel angiogenesis was quantified by measuring the cumulative length of all of the capillary-like sprouts originating from the individual spheroids using the National Institute of Health Image J programme. At least 20 spheroids per experimental group were measured in each experiment.

Animals

Male mice (6–7 weeks old, ~20 g body weight) were maintained on a standard chow pellet diet and had free access to water, with a 12 h light/dark cycles. Wild-type (WT) animals (strain C57/BL6; Charles River, Italy) were used 7 days after arrival. Groups of eight mice were used for each treatment for a total number of 40 animals. The animals were monitored daily for health status. All procedures were performed in adherence to the guidelines released by the Italian Ministry of Health (D.L.116/92) and the European Community directives regulating animal research (86/609/EEC). The results of all studies involving animals are reported in accordance with the ARRIVE guidelines (Kilkenny *et al.*, 2010; McGrath *et al.*, 2010).

In vivo angiogenesis: Matrigel sponge assay

The ability of CBD to inhibit the formation of new blood vessels *in vivo* was tested using the Matrigel sponge model as described previously (Albini *et al.*, 1994). Liquid Matrigel solutions containing an angiogenic cocktail (100 ng·mL⁻¹ VEGFA, 1.2 ng·mL⁻¹ TNF- α , and 25 U·mL⁻¹ heparin) in combination with different concentrations of CBD or vehicle alone were brought to a final volume of 0.6 mL and slowly injected s.c. into the flanks of C57/BL6 male mice (Charles River) where they formed a polymerized support. Heparin was added to avoid cytokine/growth factor trapping by proteoglycans in the Matrigel. The CBD concentrations were calculated by referring to the dose that we previously injected peritumourally in xenografts of nude mice (Massi *et al.*, 2004). Groups of eight mice were used for each treatment. Four days after injection, the gels were recovered and weighed. For haemoglobin measurements, the recovered gels were minced and dispersed in PBS. The haemoglobin released was measured using Drabkin reagent kit (Sigma) and the concentration calculated from a calibration curve after spectrophotometric analysis at 540 nm.

Statistical analysis

Results are presented as mean \pm SEM. The significance of differences was evaluated by one-way ANOVA, followed by post-hoc analysis Dunnett's *t*-test, performed with the Prism software package (GraphPad Software for Science, Inc., San Diego, CA, USA).




Figure 1

Cannabidiol inhibits the proliferation of HUVECs. HUVECs were cultured in serum-free medium with increasing concentrations of CBD. Cell proliferation was determined by MTT assay after 24 h of treatment. The proliferation was expressed as percentage of the untreated control. Data represent the mean \pm SEM of at least three independent experiments.

Nomenclature

The drug/molecular target nomenclature conforms to the BJP's Guide to Receptors and Channels (Alexander *et al.*, 2011)

Results

CBD inhibits HUVEC proliferation

We first investigated whether CBD could effect the proliferation of HUVECs. The addition of CBD to the cells for 24 h resulted in a concentration-dependent inhibition of the mitochondrial oxidative metabolism, as determined by the MTT test (Figure 1). The range of concentrations tested was from 1 μM to 19 μM . Statistically significant differences from the control were observed at concentrations of 9 μM or greater. The reduction in MTT at 9 μM was $36 \pm 2\%$, with an IC_{50} of MTT inhibition of $9.90 \pm 1.02 \mu\text{M}$. These findings indicate that CBD inhibited HUVEC proliferation, as the metabolic activity measured by MTT reflects cell number.

CBD does not induce toxicity or apoptosis in HUVECs

To verify whether CBD was cytotoxic or induced apoptosis of endothelial cells, we performed cytofluorimetric viability analyses. HUVECs were exposed to different μM concentrations of CBD for 24 h, and, after incubation, cells were analysed for both Annexin V and 7-amino-actinomycin D. A high percentage of viable cells (about 90%) was observed in all the samples, with no significant difference between the treated and untreated cells (Figure 2). These data show that CBD had no toxic effect on HUVECs, suggesting that the inhibitory effects exerted by CBD on HUVECs were not due to apoptosis or toxicity but rather cytostasis.

CBD potently inhibits HUVEC migration

To investigate if CBD is able to modulate HUVEC migration, we employed a 48-well modified Boyden chamber assay. As

shown in Figure 3A, CBD treatment caused a decrease in cell migration from 30% to 75% in the range 1–10 μM , and statistical significance was reached at 1 μM , a concentrations much lower than those inducing cytostasis (MTT test, IC_{50} $9.90 \pm 1.02 \mu\text{M}$; Figure 1).

To confirm this anti-migratory effect, we performed a cell culture wound-healing assay. Images of the cell-free wound area were taken after 16 h and 24 h. Figure 3B shows the qualitative effect of increasing CBD concentration on HUVECs at 16 h in the wound healing assay. In the control group, cells have migrated in the gap, whereas in CBD-treated cells there is a clear reduction in migration. Quantification of data showed a dose-dependent effect of CBD at inhibiting cell migration (Figure 3C) evident after 16 h of treatment and persisting for up to 24 h. Calculation of the IC_{50} indicated a value of $9.31 \pm 1.02 \mu\text{M}$, similar to that of the IC_{50} for cytostasis.

CBD modifies the expression pattern of angiogenesis-related proteins in HUVECs

Since angiogenesis depends on the activity of different proteins involved in complex pathways, we decided to analyse whether CBD interfered with the expression profile of a set of proteins involved in the angiogenic process, using a rapid and sensitive antibody array-based assay. The array images shown in Figure 4A allow a qualitative assessment of the effect of CBD on the expression pattern of multiple proteins released by HUVECs and captured by the specific pre-spotted antibodies on nitrocellulose membranes (see Methods). Eight proteins on the panel were down-regulated in response to CBD: MMP9, tissue inhibitor of metalloproteinases 1 (TIMP1), SerpinE1-plasminogen activator inhibitor type-1 (PAI-1), uPA, CXCL16, ET-1, PDGF-AA and IL-8. The extent of down-regulation ranged from 20% up to 50% as compared to the control, depending on the protein, in the presence of the highest concentration of CBD used, 12 μM (Figure 4B). The effect of CBD on the protease uPA was confirmed by Western blotting (Figure 4C), where a clear concentration-dependent reduction of expression was observed.

Given the crucial role played by MMP2 in enhancing angiogenesis, and since the levels of this protein cannot be detected by the antibody array method, we performed an ELISA assay to determine whether CBD inhibits HUVEC invasion by modulating MMP2 release into the supernatants of HUVECs. As shown in Figure 5A, after a slight increase at the lowest dose tested, CBD induces a concentration-dependent decrease in MMP2 release. Western blot analyses were also performed to evaluate the effect of CBD on the expression of MMP2 and uPA proteins extracted from HUVECs. Treatment with CBD resulted in a dose-dependent inhibition of MMP2 (Figure 5B). Zymography analysis revealed a concentration-dependent reduction in the corresponding gelatinolytic activity produced by CBD-treated HUVECs (Figure 5C).

CBD inhibits endothelial morphogenesis in vitro and the outgrowth of capillary-like structures from HUVEC spheroids

HUVECs when plated on a three-dimensional (3-D) Matrigel layer are able in 6 h to organize into capillary-like networks, mimicking *in vitro* the events that occur *in vivo* during the




Figure 2

Cannabidiol does not induce toxicity or apoptosis in endothelial cells. HUVECs were incubated in 2% FBS complete medium with increasing concentrations of CBD for 24 h. The cells were then harvested, stained with both Annexin V and 7-amino-actinomycin D, analysed and quantified by flow cytometry. (A) Representative charts indicating the proportion of apoptotic and necrotic cells. (B) Histogram representing means and SD of three different experiments.




Figure 3

Cannabidiol inhibits HUVEC migration in a concentration-dependent manner. (A) HUVECs were pretreated for 1 h with CBD, and chemotaxis experiments were then performed as described, using 10% FBS as a chemoattractant. The results are expressed as a percentage of the maximal migration induced by FBS in the absence of CBD. Mean values \pm SEM of two independent experiments performed in triplicate are shown. ** $P < 0.01$, *** $P < 0.001$ compared to untreated cells, Dunnett's t -test. (B) HUVECs were seeded in 24-well culture plates and grown for 24 h. Then, confluent monolayers were scratched with a plastic pipette tip and treated with CBD at the indicated concentrations. Images of the cell-free wound area were taken by phase contrast microscopy using a 10 \times objective, at 0 h, 16 h and 24 h. Representative images of the qualitative effect of increasing CBD concentration on HUVECs 16 h after scratch. (C) Quantification of the cells migrated into the gap, 16 h (left) and 24 h (right) after treatment. ** $P < 0.01$ versus Control (C), Dunnett's t -test.

angiogenic process (Grant *et al.*, 1989). Thus, we employed this model to characterize the *in vitro* anti-angiogenic effect of CBD. The addition of the drug partially interfered with morphogenesis of HUVECs (Figure 6A).

To confirm the results obtained, we set up a collagen gel-based 3-D angiogenesis assay where the outgrowth of capillary-like structures from HUVECs can be quantitatively measured (Korff and Augustin, 1999; Cattaneo *et al.*, 2009). Standardized spheroids were seeded in collagen gels and treated for 48 h with VEGF (30 ng·mL⁻¹) in the absence or presence of CBD (1 μM). We found that CBD significantly inhibited the VEGF-induced outgrowth of capillary-like structures from HUVEC spheroids (Figure 6B, C), confirming its ability to act, at least *in vitro*, as an anti-angiogenic factor and suggesting an effect largely on sprouting of new capillaries.

CBD inhibits *in vivo* angiogenesis

The sponge model was used as a rapid and quantitative system for measuring the *in vivo* anti-angiogenic activity of CBD dissolved in Matrigel. A s.c. injection of Matrigel produces a 3-D pellet which, when angiogenic factors are present, becomes rapidly vascularized. A cocktail of VEGF, TNF- α and heparin, mixed with the Matrigel, induced a strong angiogenic reaction (Figure 7A). When increasing con-

centrations of CBD were added to this mixture, significant inhibition of the *in vivo* angiogenic response was observed, as detected by measuring the haemoglobin content of the recovered gels (Figure 7B). At the lowest dose employed, the effect of CBD, although still significant, was lower, suggesting a dose-dependent effect.

Discussion and conclusions

Angiogenesis is a highly regulated multistep process that involves endothelial cell chemotactic migration, invasion, proliferation, differentiation into tubular capillaries, and the production of a basement membrane around the vessels (Folkman, 1995; Kesisis *et al.*, 2007). In this study, CBD exhibited potent anti-angiogenic properties, inhibiting HUVEC growth, migration and invasion *in vitro* as well as angiogenesis in the Matrigel sponge assay *in vivo*. Molecular studies *in vitro* demonstrated that CBD exerts its effects through the down-regulation of several angiogenic mechanisms. Taken together, these data suggest that CBD has great potential as a new anti-angiogenic drug.

Our results demonstrated that CBD was effective in inhibiting endothelial cell proliferation without inducing




Figure 4

Cannabidiol affects the protein expression profile of HUVECs. (A) HUVECs were treated with CBD for 24 h and supernatants were used to determine different protein levels through a human antibody array kit/proteome profiler. Representative proteomic membrane analysis with the indication of proteins modified. (B) Densitometric analysis of the membrane spots reported as percentage of the untreated control. Data represent the mean \pm SEM of three independent experiments. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ versus Control, Dunnett's *t*-test. (C) Western blot analysis of 5B4 antibody against uPA. A representative Western blot is shown. NT, not treated.

endothelial cell apoptosis or necrosis, suggesting a cytostatic action. Several chemotherapeutic drugs have anti-angiogenic properties only at near or fully cytotoxic concentrations; therefore, their clinical relevance is controversial. Interestingly, CBD did not induce HUVEC apoptosis or necrosis even at the highest dose tested (12 μ M). Several anti-angiogenic molecules inhibit endothelial cell proliferation, without exerting any cytotoxic action and can even inhibit apoptosis in endothelial cells (Fassina *et al.*, 2004; Lorusso *et al.*, 2009; Noonan *et al.*, 2011b). This seems to be in contrast to their effects on tumour cells, where often these compounds are cytotoxic, at least at high doses. However, this may depend on several characteristics of tumour cells, including chronic stress related to high-level production of oxygen and other radicals, metabolic alterations and oncogene dependence (Ferrari *et al.*, 2010). Further cellular stress in tumour cells pushes the cell over the threshold and into apoptosis, whereas in normal cells, this may act as a form of 'preconditioning' stimulus that renders the cells more resistant to subsequent insults (Ferrari *et al.*, 2010).

CBD's lack of cytotoxicity towards endothelial cells is quite different from that reported in previous studies with other cannabinoids (Blázquez *et al.*, 2003). In these studies, endothelial cell cytotoxicity was considered a potential mechanism of action. Our data suggest that, unlike other cannabinoids, the effects of CBD are not due to endothelial cell toxicity but rather to modulation of intracellular pathways leading to a decrease in several pro-angiogenic factors.

CBD showed potent inhibition of endothelial cell migration, both in the scratch wound-healing assay and, with an even stronger effect, in the Boyden chamber assay. The different efficacy of CBD in these tests could be ascribed to the different sensitivity of the assays, since the wound-healing assay is generally less sensitive than the Boyden chamber. Moreover, the use of primary fresh HUVECs in the Boyden chamber in comparison with the commercially available cells employed in the wound-healing assay could account for the different potency observed. However, in our hands, CBD elicited significant effects on migration at concentrations lower than those causing 50% inhibition of proliferation (9 μ M and




Figure 5

Cannabidiol affects the expression of MMP2. (A) HUVECs were treated with CBD for 24 h and the MMP2 levels in supernatants were determined by ELISA. Protein levels in the different experimental conditions, compared with Control, of three independent experiments are shown. $**P < 0.01$ versus Control (C), Dunnett's *t*-test. (B) Western blot analysis of MMP2. A representative Western blot is shown. NT, not treated. A human MMP2 protein (MMP2) was used as a standard. (C) Representative zymogram corresponding to the expression and gelatinolytic activity of MMP2 by HUVECs treated with different concentrations of CBD. A human MMP2 protein (MMP2) was used as a standard.

1 μM , respectively, in wound healing and Boyden chamber assays versus IC_{50} value of 10 μM in the MTT assay run in parallel to the migration tests). We previously demonstrated the same order of potency of CBD on U87-MG glioma cell proliferation versus invasion (Vaccani *et al.*, 2005). In agreement with these results, Marcu *et al.* (2010) showed that CBD was more potent at inhibiting U251 invasiveness compared to their proliferation. Thus, similar to glioma, CBD is highly potent at inhibiting endothelial cell migration compared to proliferation, suggesting that factors influencing cell migration and invasion may represent its primary targets.

In line with this, our molecular investigation showed that CBD affected the expression of several prominent factors involved in primary vascular endothelial cell functions; in particular compounds that induce invasion and migration, which included MMP2 and MMP9, TIMP1, SerpinE1/PAI1, uPA, CXCL16, IL-8, ET-1 and PDGF-AA.

CBD inhibited MMP2 and MMP9, two fundamental proteases that, through the remodelling of the extracellular matrix and basement membrane, are involved in distinct vascular events, and whose levels are increased in numerous malignancies, including glioma (Cantelmo *et al.*, 2010; Pisanti *et al.*, 2011; Noonan *et al.*, 2011b).

CBD down-regulated the expression of TIMP1, a stromal factor with multiple functions. TIMPs are commonly described as negative regulators of MMPs. Nasser *et al.* (2006) showed that TIMP1 is an inhibitor of high-grade glioma invasion. In line with this, Ramer *et al.* (2010a) recently reported a CBD-driven increase in TIMP1 in lung cancer cells that correlated with diminished invasiveness. Nevertheless, there is increasing evidence to suggest that TIMPs are multifunc-

tional proteins, possessing a dual role in regulating cell proliferation and angiogenesis. *In vitro*, TIMP1 promotes growth of human keratinocytes and several other cell types (Bertaux *et al.*, 1991; Hayakawa *et al.*, 1992), inhibits apoptosis (Alexander *et al.*, 1996; Guedez *et al.*, 1998; Li *et al.*, 1999) and regulates angiogenesis (Yoshiji *et al.*, 1998; Lafleur *et al.*, 2002). Moreover, increased expression of TIMP1 protein has been observed in multiple tumour types, including breast, colon, gastric and lung cancers, as well as in lymphoma and carcinomas of unknown primary origin (Zeng *et al.*, 1995; Mimori *et al.*, 1997; Ree *et al.*, 1997; Guedez *et al.*, 2001; Schrohl *et al.*, 2004; Gouyer *et al.*, 2005; Karavasilis *et al.*, 2005).

Based on these considerations, it is noteworthy that inhibition of proteins such as MMP2 and MMP9 and TIMP1 further confirms the wide spectrum of CBD action on MMP and TIMP molecules, key factors in cell motility, invasion and proliferation, and suggests a complex picture through which CBD can impair cell growth and invasion.

In addition to the MMP/TIMP system, CBD also down-regulated the uPA and the plasminogen activator inhibitor SerpinE1/PAI-1, two important factors in extracellular matrix remodelling and consequent angiogenesis. The uPA plays a pivotal role in the degradation of extracellular matrix, and suppression of uPA and uPAR by shRNA attenuates angiogenin-mediated angiogenesis in endothelial and glioblastoma cell lines (Raghu *et al.*, 2010). Thus, CBD shares similarities with other therapeutic approaches that, by inhibiting the uPA/uPAR functions, have been shown to possess anti-angiogenic and anti-tumour effects (for review, see Ulisse *et al.*, 2009).




Figure 6

Cannabidiol inhibits *in vitro* endothelial morphogenesis and angiogenesis. (A) HUVECs were incubated on a Matrigel substrate in the presence of M199 alone (Control -) or of M199 supplemented with 2% FBS (Control +), in the absence or presence of different concentrations of CBD for 6 h at 37°C. CBD interfered with HUVEC organization in capillary-like networks. (B) HUVEC spheroids, generated as described in the 'Methods' section, were embedded in collagen gel supplemented with VEGF (30 ng·mL⁻¹) in the absence (Control) or in the presence of CBD (1 μM). Representative photos of each experimental group are shown. (C) Quantification of the sprouting. The results are expressed as the mean ± SEM of the cumulative sprout length of the capillary-like structures emerging from 24 to 26 individual spheroids per experimental group. ***P* < 0.01 compared to spheroids from control HUVECs, Dunnett's *t*-test.

Since SerpinE1/PAI-1 inhibits uPA, low levels of this protein would be expected to favour cell growth. However, recent data have revealed a two-faced role in the modulation of apoptosis in tumour cells in comparison with non-tumour cells. At present, the reason for these discrepant effects is still unclear and some recent reports point to other multifunctional roles of this protein in angiogenesis, invasiveness and cell adhesion (Ulisse *et al.*, 2009).

CBD also significantly inhibited two potent angiogenic factors: the chemokines CXCL16 and IL-8 (Rabquer *et al.*, 2011). Stimulation of HUVECs with CXCL16 leads to increases in cell proliferation, chemotactic motility and network formation (Zhuge *et al.*, 2005), whereas IL-8 can induce angiogenesis through both direct and indirect mechanisms (Benelli *et al.*, 2002; 2003; Lai *et al.*, 2011). The decreased level of both chemokines following CBD treatment

would be consistent with its *in vitro* and *in vivo* anti-angiogenic effects.

Two growth factors were also down-regulated by CBD: ET-1 and PDGF-AA. ETs modulate various stages of neovascularization. Increased levels of ET-1 and its cognate receptor are significantly associated with microvessel density and VEGF expression in tumour cells, whereas its down-regulation correlates well with diminished endothelial cell growth and migration (Bagnato *et al.*, 2008).

PDGF-AA is a member of the well-known PDGF family that exerts its angiogenic effect in endothelial cells by binding to a specific protein tyrosine kinase receptor, which in its turn engages several signalling molecules involved in multiple cellular and developmental responses.

Taken together, these observations suggest a broad effect of CBD on vascular endothelial cell biology. This wide




Figure 7

Cannabidiol inhibits *in vivo* angiogenesis. Matrigel sponges containing angiogenic factors (VEGF, TNF- α and heparin) become rapidly vascularized when implanted s.c. as assayed by measurement of haemoglobin content on the fourth day after implantation. Representative images of the excised pellets are shown. CBD dissolved in the Matrigel significantly inhibited angiogenesis (from 0.0625 mg per pellet and above), detectable by visual inspection (A) and quantified by measuring haemoglobin (Hb) content of the pellets (B). ** $P < 0.01$ versus Control (C), Dunnett's *t*-test.

spectrum modulation of angiogenesis-related factors leads to a decreased ability of endothelial cells to properly form new vessels *in vitro* and, to an even more prominent extent, impaired angiogenesis in *in vivo* plugs.

However, the molecular mechanism through which CBD exerts these effects still remains unknown. Vascular endothelial cells express various functional receptors for cannabinoids, including the CB₁ receptor (Liu *et al.*, 2000), the CB₂ receptor (Blázquez *et al.*, 2003), the tentative abnormal CBD receptor (Járai *et al.*, 1999), the TRP receptors (Golech *et al.*, 2004; Curry and Glass, 2006; Kwan *et al.*, 2007) and the PPAR γ (O'Sullivan *et al.*, 2009; Yokoyama *et al.*, 2011): each of these could, at least in part, be involved in CBD anti-angiogenic effects. These receptors control important cell functions such as migration (Blázquez *et al.*, 2003; Mo *et al.*, 2004), survival (Blázquez *et al.*, 2003), vascular tone (Wagner *et al.*, 1997; Bátkaï *et al.*, 2001) and tumour-derived endothelial cell migration (Fiorio Pla *et al.*, 2012). Recently, blockade of the CB₁ receptor has been closely linked to inhibition of angiogenesis (Pisanti *et al.*, 2011). Our present data do not allow us to indicate a receptor-dependent versus -independent mechanism of CBD in HUVECs. Since both cannabinoid-dependent (McKallip *et al.*, 2002; 2006; Ligresti *et al.*, 2006; Ramer *et al.*, 2010a,b; Aviello *et al.*, 2012) and -independent (Massi *et al.*, 2004; Vaccani *et al.*, 2005; Shrivastava *et al.*, 2011) mechanisms were previously shown for CBD anti-tumour effects, it is also possible that its anti-angiogenic activity may be due to a receptor-independent mechanism, involving different primary cellular targets. In line with this, recent studies (McAllister *et al.*, 2007; 2011) have demonstrated that the anti-invasive and anti-proliferative effects of CBD in breast cancer are closely associated with inhibition of Id-1, an inhibitor of basic helix-loop-helix transcription factors that is over-expressed in tumour cells. Id proteins play a vital role in regulating angiogenesis during embryonic development and tumourigenesis and ectopic Id-1 expression

in HUVECs leads to increased migration of the cells, while suppression of its endogenous expression results in reduced migration (Qiu *et al.*, 2011). Thus, Id-1 could represent a key signalling pathway for CBD in HUVECs.

In conclusion, our results indicate that CBD exerts a potent anti-angiogenic effect by widely affecting several pathways involved in this process. Its dual effect on both tumour and endothelial cells further suggests that CBD could represent a potential effective agent in cancer therapy.

Acknowledgements

The authors wish to thank GW Pharmaceuticals for providing CBD and financial support to conduct these studies. These studies were also funded by the AIRC (Associazione Italiana per la Ricerca sul Cancro) to AA and DMN. We thank Prof. Mario Del Rosso (Department of Experimental Pathology and Oncology, University of Florence) for kindly providing the human anti-MMP2 and anti-uPA (5B4 clone) antibodies.

Conflicts of Interest

This research work was partially funded by GW Pharmaceuticals.

References

Albini A, Fontanini G, Masiello L, Tacchetti C, Bigini D, Luzzi P *et al.* (1994). Angiogenic potential *in vivo* by Kaposi's sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. *AIDS* 8: 1237-1244.

- Albini A, Brigati C, Ventura A, Lorusso G, Pinter M, Morini M *et al.* (2009). Angiostatin anti-angiogenesis requires IL-12: the innate immune system as a key target. *J Transl Med* 14: 7–5.
- Albini A, Indraccolo S, Noonan DM, Pfeffer U (2010). Functional genomics of endothelial cells treated with anti-angiogenic or angiopreventive drugs. *Clin Exp Metastasis* 27: 419–439.
- Alexander A, Smith PF, Rosengren RJ (2009). Cannabinoids in the treatment of cancer. *Cancer Lett* 285: 6–12.
- Alexander CM, Howard EW, Bissell MJ, Werb Z (1996). Rescue of mammary epithelial apoptosis and entactin degradation by a tissue inhibitor of metalloproteinase-1 transgene. *J Cell Biol* 135: 1669–1677.
- Alexander SPH, Mathie A, Peters JA (2011). Guide to receptors and channels (GRAC), 5th edition. *Br J Pharmacol* 164 (Suppl. 1): S1–S324.
- Aviello G, Romano B, Borrelli F, Capasso R, Gallo L, Piscitelli F *et al.* (2012). Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer. *J Mol Med* DOI: 10.1007/s00109-011-0856-x [Epub ahead of print].
- Bagnato A, Spinella F, Rosanò L (2008). The endothelin axis in cancer: the promise and the challenges of molecularly targeted therapy. *Can J Physiol Pharmacol* 86: 473–484.
- Bátkai S, Járαι Z, Wagner JA, Goparaju SK, Varga K, Liu J *et al.* (2001). Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. *Nat Med* 7: 827–832.
- Benelli R, Morini M, Carrozzino F, Ferrari N, Minghelli S, Santi L *et al.* (2002). Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. *FASEB J* 16: 267–269.
- Benelli R, Albini A, Noonan D (2003). Neutrophils and angiogenesis: potential initiators of the angiogenic cascade. In: Cassatella MA (ed.). *The Neutrophil: An Emerging Regulator of Inflammatory and Immune Response*. Karger: Basel, pp. 167–181.
- Bertaux B, Hornebeck W, Eisen AZ, Dubertret L (1991). Growth stimulation of human keratinocytes by tissue inhibitor of metalloproteinases. *J Invest Dermatol* 97: 679–685.
- Blázquez C, Casanova ML, Planas A, Gómez del Pulgar T, Villanueva C, Fernández-Aceñero MJ *et al.* (2003). Inhibition of tumor angiogenesis by cannabinoids. *FASEB J* 17: 529–531.
- Blázquez C, González-Feria L, Alvarez L, Haro A, Casanova ML, Guzmán M (2004). Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. *Cancer Res* 64: 5617–5623.
- Blázquez C, Carracedo A, Barrado L, Real PJ, Fernández-Luna JL, Velasco G *et al.* (2006). Cannabinoid receptors as novel targets for the treatment of melanoma. *FASEB J* 20: 2633–2635.
- Cantelmo AR, Cammarota R, Noonan DM, Focaccetti C, Comoglio PM, Prat M *et al.* (2010). Cell delivery of Met docking site peptides inhibit angiogenesis and vascular tumor growth. *Oncogene* 29: 5286–5298.
- Casanova ML, Blázquez C, Martínez-Palacio J, Villanueva C, Fernández-Aceñero MJ, Huffman JW *et al.* (2003). Inhibition of skin tumor growth and angiogenesis *in vivo* by activation of cannabinoid receptors. *J Clin Invest* 111: 43–50.
- Cattaneo MG, Chini B, Vicentini LM (2008). Oxytocin stimulates migration and invasion in human endothelial cells. *Br J Pharmacol* 153: 728–736.
- Cattaneo MG, Lucci G, Vicentini LM (2009). Oxytocin stimulates *in vitro* angiogenesis via a Pyk-2/Src-dependent mechanism. *Exp Cell Res* 315: 3210–3219.
- Chung AS, Lee J, Ferrara N (2010). Targeting the tumour vasculature: insights from physiological angiogenesis. *Nat Rev Cancer* 10: 505–514.
- Curry FR, Glass CA (2006). TRP channels and the regulation of vascular permeability: new insights from the lung microvasculature. *Circ Res* 99: 915–917.
- De Petrocellis L, Ligresti A, Moriello AS, Allarà M, Bisogno T, Petrosino S *et al.* (2011). Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. *Br J Pharmacol* 163: 1479–1494.
- Fassina G, Venè R, Morini M, Minghelli S, Benelli R, Noonan DM *et al.* (2004). Mechanisms of inhibition of tumor angiogenesis and vascular tumor growth by epigallocatechin-3-gallate. *Clin Cancer Res* 10: 4865–4873.
- Ferrari N, Tosetti F, De Flora S, Donatelli F, Noonan DM, Albini A (2010). Diet-derived phytochemicals: from cancer chemoprevention to cardio-oncological prevention. *Curr Drug Targets* 12: 1909–1924.
- Fiorio Pla A, Avanzato D, Munaron L, Ambudkar IS (2012). Ion channels and transporters in cancer. 6. Vascularizing the tumor: TRP channels as molecular targets. *Am J Physiol Cell Physiol* 302: C9–C15.
- Flygare J, Sander B (2008). The endocannabinoid system in cancer-potential therapeutic target? *Semin Cancer Biol* 18: 176–189.
- Folkman J (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat Med* 1: 27–31.
- Folkman J (2007). Angiogenesis: an organizing principle for drug discovery? *Nat Rev Drug Discov* 6: 273–286.
- Freimuth N, Ramer R, Hinz B (2010). Antitumorogenic effects of cannabinoids beyond apoptosis. *J Pharmacol Exp Ther* 332: 336–344.
- Gertsch J, Pertwee RG, Di Marzo V (2010). Phytocannabinoids beyond the Cannabis plant – do they exist? *Br J Pharmacol* 160: 523–529.
- Golech SA, McCarron RM, Chen Y, Bembry J, Lenz F, Mechoulam R *et al.* (2004). Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. *Brain Res Mol Brain Res* 132: 87–92.
- Gouyer V, Conti M, Devos P, Zerimech F, Copin MC, Crème E *et al.* (2005). Tissue inhibitor of metalloproteinase-1 is an independent predictor of prognosis in patients with non-small cell lung carcinoma who undergo resection with curative intent. *Cancer* 103: 1676–1684.
- Grant DS, Tashiro K, Segui-Real B, Yamada Y, Martin GR, Kleinman HK (1989). Two different laminin domains mediate the differentiation of human endothelial cells into capillary-like structures *in vitro*. *Cell* 58: 933–943.
- Guedez L, Stetler-Stevenson WG, Wolff L, Wang J, Fukushima P, Mansoor A *et al.* (1998). *In vitro* suppression of programmed cell death of B cells by tissue inhibitor of metalloproteinases-1. *J Clin Invest* 102: 2002–2010.
- Guedez L, McMarlin AJ, Kingma DW, Bennett TA, Stetler-Stevenson M, Stetler-Stevenson WG (2001). Tissue inhibitor of metalloproteinase-1 alters the tumorigenicity of Burkitt's lymphoma via divergent effects of tumor growth and angiogenesis. *Am J Pathol* 158: 1207–1215.

- Guindon J, Hohmann AG (2011). The endocannabinoid system and cancer: therapeutic implication. *Br J Pharmacol* 163: 1447–1463.
- Hayakawa T, Yamashita K, Tanzawa K, Uchijima E, Iwata K (1992). Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. *FEBS Lett* 298: 29–32.
- Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). NC3Rs Reporting Guidelines Working Group. *Br J Pharmacol* 160: 1577–1579.
- Jaffe EA, Nachman RL, Becker CG, Minick CR (1973). Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunological criteria. *J Clin Invest* 52: 2745–2756.
- Járai Z, Wagner JA, Varga K, Lake KD, Compton DR, Martin BR *et al.* (1999). Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. *Proc Natl Acad Sci U S A* 96: 14136–14141.
- Karavasili V, Malamou-Mitsi V, Briasoulis E, Tsanou E, Kitsou E, Kalofonos H *et al.* (2005). Matrix metalloproteinases in carcinoma of unknown primary. *Cancer* 104: 2282–2287.
- Kesisis G, Broxterman H, Giaccone G (2007). Angiogenesis inhibitors. Drug selectivity and target specificity. *Curr Pharm Des* 13: 2795–2809.
- Korff T, Augustin HG (1998). Integration of endothelial cells in multicellular spheroids prevents apoptosis and induces differentiation. *J Cell Biol* 143: 1341–1352.
- Korff T, Augustin HG (1999). Tensional forces in fibrillar extracellular matrices control directional capillary sprouting. *J Cell Sci* 112: 3249–3258.
- Kwan HY, Huang Y, Yao X (2007). TRP channels in endothelial function and dysfunction. *Biochim Biophys Acta* 1772: 907–914.
- Lafleur MA, Handsley MM, Knäuper V, Murphy G, Edwards DR (2002). Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type matrix metalloproteinases (MT-MMPs). *J Cell Sci* 115: 3427–3428.
- Lai Y, Shen Y, Liu XH, Zhang Y, Zeng Y, Liu YF (2011). Interleukin-8 induces the endothelial cell migration through the activation of phosphoinositide 3-kinase-Rac1/RhoA pathway. *Int J Biol Sci* 7: 782–791.
- Li G, Fridman R, Kim HR (1999). Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. *Cancer Res* 59: 6267–6275.
- Ligresti A, Moriello AS, Starowicz K, Matias I, Pisanti S, De Petrocellis L *et al.* (2006). Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. *J Pharmacol Exp Ther* 318: 1375–1387.
- Liu J, Gao B, Mirshahi F, Sanyal AJ, Khanolkar AD, Makriyannis A *et al.* (2000). Functional CB1 cannabinoid receptors in human vascular endothelial cells. *Biochem J* 346: 835–840.
- Lorusso G, Vannini N, Sogno I, Generoso L, Garbisa S, Noonan DM *et al.* (2009). Mechanisms of hyperforin as an anti-angiogenic angioprevention agent. *Eur J Cancer* 45: 1474–1484.
- Marcu JP, Christian RT, Lau D, Zielinski AJ, Horowitz MP, Lee J *et al.* (2010). Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. *Mol Cancer Ther* 9: 180–189.
- Massi P, Vaccani A, Ceruti S, Colombo A, Abbraccio MP, Parolaro D (2004). Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. *J Pharmacol Exp Ther* 308: 838–845.
- Massi P, Vaccani A, Bianchessi S, Costa B, Macchi P, Parolaro D (2006). The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. *Cell Mol Life Sci* 63: 2057–2066.
- Massi P, Valenti M, Vaccani A, Gasperi V, Perletti G, Marras E *et al.* (2008). 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. *J Neurochem* 104: 1091–1100.
- McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY (2007). Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. *Mol Cancer Ther* 6: 2921–2927.
- McAllister SD, Murase R, Christian RT, Lau D, Zielinski AJ, Allison J *et al.* (2011). Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. *Breast Cancer Res Treat* 129: 37–47.
- McKallip RJ, Lombard C, Fisher M, Martin BR, Ryu S, Grant S *et al.* (2002). Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease. *Blood* 100: 627–634.
- McKallip RJ, Jia W, Schlomer J, Warren JW, Nagarkatti PS, Nagarkatti M (2006). Cannabidiol-induced apoptosis in human leukemia cells: a novel role of cannabidiol in the regulation of p22phox and Nox4 expression. *Mol Pharmacol* 70: 897–908.
- McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. *Br J Pharmacol* 160: 1573–1576.
- Mimori K, Mori M, Shiraishi T, Fujie T, Baba K, Haraguchi M *et al.* (1997). Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. *Br J Cancer* 76: 531–536.
- Mo FM, Offertáler L, Kunos G (2004). Atypical cannabinoid stimulates endothelial cell migration via a Gi/Go-coupled receptor distinct from CB1, CB2 or EDG-1. *Eur J Pharmacol* 489: 21–27.
- Nasser JA, Falavigna A, Ferraz F, Duigou G, Bruce J (2006). Transcription analysis of TIMP-1 and NM23-H1 genes in glioma cell invasion. *Arq Neuropsiquiatr* 64: 774–780.
- Noonan DM, De Lerma Barbaro A, Vannini N, Mortara L, Albini A (2008). Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. *Cancer Metastasis Rev* 27: 31–40.
- Noonan DM, Ventura A, Bruno A, Pagani A, Albini A (2011a). The angiogenic switch: role of immune cells. In: Wang E, Marincola F (eds). *Immunologic Signatures of Rejection*. Springer: New York, pp. 57–75.
- Noonan DM, Sogno I, Albini A (2011b). Plants and plant-derived products as cancer chemopreventive agents. In: Bagetta G, Cosentino M, Corasaniti MT, Sakurada S (eds). *Herbal Medicines: Development and Validation of Plant-Derived Medicines for Human Health*. CRC Press Inc: Boca Raton, FL, pp. 285–306.
- O'Sullivan SE, Kendall DA (2010). Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. *Immunobiology* 215: 611–616.
- O'Sullivan SE, Sun Y, Bennett AJ, Randall MD, Kendall DA (2009). Time-dependent vascular actions of cannabidiol in the rat aorta. *Eur J Pharmacol* 612: 61–68.
- Pisanti S, Borselli C, Oliviero O, Laezza C, Gazzero P, Bifulco M (2007). Antiangiogenic activity of the endocannabinoid anandamide: correlation to its tumor-suppressor efficacy. *J Cell Physiol* 211: 495–503.

- Pisanti S, Picardi P, Prota L, Proto MC, Laezza C, McGuire PG *et al.* (2011). Genetic and pharmacologic inactivation of cannabinoid CB1 receptor inhibits angiogenesis. *Blood* 117: 5541–5550.
- Portella G, Laezza C, Laccetti P, De Petrocellis L, Di Marzo V, Bifulco M (2003). Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. *FASEB J* 17: 1771–1773.
- Preet A, Ganju RK, Groopman JE (2008). Delta9-tetrahydrocannabinol inhibits epithelial growth factor-induced lung cancer cell migration *in vitro* as well as its growth and metastasis *in vivo*. *Oncogene* 27: 339–346.
- Qiu J, Wang G, Hu J, Peng Q, Zheng Y (2011). Id1-induced inhibition of p53 facilitates endothelial cell migration and tube formation by regulating the expression of beta1-integrin. *Mol Cell Biochem* 357: 125–133.
- Rabquer BJ, Tsou PS, Hou Y, Thirunavukkarasu E, Haines GK 3rd, Impens AJ *et al.* (2011). Dysregulated expression of MIG/CXCL9, IP-10/CXCL10 and CXCL16 and their receptors in systemic sclerosis. *Arthritis Res Ther* 13: R18.
- Raghu H, Lakka SS, Gondi CS, Mohanam S, Dinh DH, Gujrati M *et al.* (2010). Suppression of uPA and uPAR attenuates angiogenin mediated angiogenesis in endothelial and glioblastoma cell lines. *PLoS ONE* 5: e12458.
- Ramer R, Merkord J, Rohde H, Hinz B (2010a). Cannabidiol inhibits cancer cell invasion via upregulation of tissue inhibitor of matrix metalloproteinases-1. *Biochem Pharmacol* 79: 955–966.
- Ramer R, Rohde A, Merkord J, Rohde H, Hinz B (2010b). Decrease of plasminogen activator inhibitor-1 may contribute to the anti-invasive action of cannabidiol on human lung cancer cells. *Pharm Res* 27: 2162–2174.
- Ree AH, Florenes VA, Berg JP, Maelandsmo GM, Nesland JM, Fodstad O (1997). High levels of messenger RNAs for tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2) in primary breast carcinomas are associated with development of distant metastases. *Clin Cancer Res* 3: 1623–1628.
- Russo EB (2011). Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *Br J Pharmacol* 163: 1344–1364.
- Schrohl AS, Holten-Andersen MN, Peters HA, Look MP, Meijer-van Gelder ME, Klijn JG *et al.* (2004). Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. *Clin Cancer Res* 10: 2289–2298.
- Shrivastava A, Kuzontkoski PM, Groopman JE, Prasad A (2011). Cannabidiol induces programmed cell death in breast cancer cells by coordinating the cross-talk between apoptosis and autophagy. *Mol Cancer Ther* 10: 1161–1172.
- Torres S, Lorente M, Rodríguez-Fornés F, Hernández-Tiedra S, Salazar M, García-Taboada E *et al.* (2011). A combined preclinical therapy of cannabinoids and temozolomide against glioma. *Mol Cancer Ther* 10: 90–103.
- Ulisse S, Baldini E, Sorrenti S, D'Armiento M (2009). The urokinase plasminogen activator system: a target for anti-cancer therapy. *Curr Cancer Drug Targets* 9: 32–71.
- Vaccani A, Massi P, Colombo A, Rubino T, Parolaro D (2005). Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism. *Br J Pharmacol* 144: 1032–1036.
- Wagner JA, Varga K, Ellis EF, Rzigalinski BA, Martin BR, Kunos G (1997). Activation of peripheral CB1 cannabinoid receptors in haemorrhagic shock. *Nature* 390: 518–521.
- Yokoyama Y, Xin B, Shigeto T, Mizunuma H (2011). Combination of ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, and cisplatin enhances the inhibition of growth of human ovarian cancers. *J Cancer Res Clin Oncol* 137: 1219–1228.
- Yoshiji J, Harris SR, Raso E, Gomez DE, Lindsay CK, Shibuya M *et al.* (1998). Mammary carcinoma cells overexpressing tissue inhibitor of metalloproteinases-1 show enhanced vascular endothelial growth factor expression. *Int J Cancer* 75: 81–87.
- Zeng ZS, Cohen AM, Zhang ZF, Stetler-Stevenson W, Guillem JG (1995). Elevated tissue inhibitor of metalloproteinase I RNA in colorectal cancer stroma correlates with lymph node and distant metastases. *Clin Cancer Res* 1: 899–906.
- Zhuge X, Murayama T, Arai H, Yamauchi R, Tanaka M, Shimaoka T *et al.* (2005). CXCL16 is a novel angiogenic factor for human umbilical vein endothelial cells. *Biochem Biophys Res Commun* 331: 1295–1300.